Podium to Practice: ASH® 2025 – MULTIPLE MYELOMA: Early DPd Rescue in High-Risk Smoldering Myeloma Post-KRd-ASCT: GEM-CESAR Study

Podium to Practice: ASH® 2025 – MULTIPLE MYELOMA: Early DPd Rescue in High-Risk Smoldering Myeloma Post-KRd-ASCT: GEM-CESAR Study

Podium to Practice: ASH® 2025
Explore more from your favourite experts – click their name to access their entire library of content.
Icon Chair Speaker

Chair

Dr. Donna Reece

Icon Chair Speaker

Speakers

Dr. Darrell White

Dr. Maria Victoria Mateos Manteca

Studies / Trials Discussed

ID 371 – Early rescue intervention with daratumumab, pomalidomide and dexamethasone (DPd) in high-risk smoldering myeloma (HR-SMM) patients included in the GEM-CESAR treated with carfilzomib, lenalidomide and dexamethasone (KRd)- autologous stem cell transplantation (ASCT)-krd-rd

Studies/trials discussed:

ID 371 – Early rescue intervention with daratumumab, pomalidomide and dexamethasone (DPd) in high-risk smoldering myeloma (HR-SMM) patients included in the GEM-CESAR treated with carfilzomib, lenalidomide and dexamethasone (KRd)- autologous stem cell transplantation (ASCT)-krd-rd
Tagged